CryoPort Inc. has developed an innovative, proprietary, technology-driven transport and packaging system focused on providing a solution that replaces dry ice for the frozen shipping market in the global life science industry. The company’s products have a 10+ day holding time, use ‘green’ materials and are essential components of the infrastructure for the testing and research of temperature sensitive medicines and biomaterials.
The company today announced that it has significantly expanded its marketing and sales operations by naming Mark Engelhart as senior vice-president and chief commercial officer, and Damon Baca and Tony Goffe as senior directors of sales. With next-generation frozen shipping options now available at FedEx and others, CryoPort feels now is the time to leverage their efforts and take advantage of the expanding business opportunities.
Mark Engelhart has spent more than 30 years in the pharmaceutical, biotechnology and contract research organizations industries, with a track record of successfully developing and executing marketing and sales strategies. His prior experience includes stints at Bayer, Abbot Laboratories, Quest Diagnostics and Covance.
Damon Baca has more than 10 years of international sales and sales management experience. Most recently, he was a global sales executive and supply chain specialist with FedEx in Sweden where his clients included AstraZeneca, one of the world’s largest pharmaceutical companies.
Tony Goffe was previously a training supervisor and strategic account sales manager for United Parcel Service in Seattle where his clients included medical and biotechnology companies. He also has significant experience in product development and management with biotechnology and life sciences companies including Monsanto, Sepracor and CellPro.
For more information about CyroPort, please visit its website at cryoport.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.